Rui Teles

Dr. Rui Teles

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
MSMatheus Simonato
Matheus Simonato
BWBrian Whisenant
Brian Whisenant
HRHenrique Ribeiro
Henrique Ribeiro
JWJohn G. Webb
John G. Webb
RKRan Kornowski
Ran Kornowski
DDDanny Dvir
Danny Dvir
Background: Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous surgical valve repair or replacement. Our aim was to perform a large-scale analysis examining midterm outcomes after mitral ViV and ViR. Methods: Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve International Data Registry. Cases were performed between March 2006 and March 2020. Clinical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) definitions. Significant residual mitral stenosis (MS) was defined as mean gradient ≥10 mm Hg and significant residual mitral regurgitation (MR) as ≥ moderate. Results: A total of 1079 patients (857 ViV, 222 ViR; mean age 73.5±12.5 years; 40.8% male) from 90 centers were included. Median STS-PROM score 8.6%; median clinical follow-up 492 days (interquartile range, 76–996); median echocardiographic follow-up for patients that survived 1 year was 772.5 days (interquartile range, 510–1211.75). Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR ( P <0.001). Mean gradient across the mitral valve postprocedure was 5.7±2.8 mm Hg (≥5 mm Hg; 61.4% of patients). Significant residual MS occurred in 8.2% of the ViV and 12.0% of the ViR patients ( P =0.09). Significant residual MR was more common in ViR patients (16.6% versus 3.1%; P <0.001) and was associated with lower survival at 4 years (35.1% versus 61.6%; P =0.02). The rates of Mitral Valve Academic Research Consortium–defined device success were low for both procedures (39.4% total; 32.0% ViR versus 41.3% ViV; P =0.01), mostly related to having postprocedural mean gradient ≥5 mm Hg. Correlates for residual MS were smaller true internal diameter, younger age, and larger body mass index. The only correlate for residual MR was ViR. Significant residual MS (subhazard ratio, 4.67; 95% CI, 1.74–12.56; P =0.002) and significant residual MR (subhazard ratio, 7.88; 95% CI, 2.88–21.53; P <0.001) were both independently associated with repeat mitral valve replacement. Conclusions: Significant residual MS and/or MR were not infrequent after mitral ViV and ViR procedures and were both associated with a need for repeat valve replacement. Strategies to improve postprocedural hemodynamics in mitral ViV and ViR should be further explored.

1 September 2021 in Atherosclerosis
Verified
Journal Article
Closed access
Leonardo De LucaLeonardo De Luca
Leonardo De Luca
NDNiels Debel
Niels Debel
MCMiha Cercek
Miha Cercek
LJLisette Okkels Jensen
Lisette Okkels Jensen
MVMarija Vavlukis
Marija Vavlukis
MVMonica Verdoia
Monica Verdoia

1 June 2021 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
Luca TestaLuca Testa
Luca Testa
MAMauro Agnifili
Mauro Agnifili
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem
DTDidier Tchétché
Didier Tchétché
AAAnita W. Asgar
Anita W. Asgar
FBFrancesco Bedogni
Francesco Bedogni
Background: Transcatheter aortic valve replacement (TAVR) has determined a paradigm shift in the treatment of patients with severe aortic stenosis. However, the durability of bioprostheses is still a matter of concern, and little is known about the management of degenerated TAV. We sought to evaluate the outcomes of patients with a degenerated TAV treated by means of a second TAVR. Methods: The TRANSIT is an international registry that included cases of degenerated TAVR from 28 centers. Among around 40 000 patients treated with TAVR in the participating centers, 172 underwent a second TAVR: 57 (33%) for a mainly stenotic degenerated TAV, 97 (56%) for a mainly regurgitant TAV, and 18 (11%) for a combined degeneration. Overall, the rate of New York Heart Association class III/IV at presentation was 73.5%. Results: Valve Academic Research Consortium 2 device success rate was 79%, as a consequence of residual gradient (14%) or regurgitation (7%). At 1 month, the overall mortality rate was 2.9%, while rates of new hospitalization and New York Heart Association class III/IV were 3.6% and 7%, respectively, without significant difference across the groups. At 1 year, the overall mortality rate was 10%, while rates of new hospitalization and New York Heart Association class III/IV were 7.6% and 5.8%, respectively, without significant difference across the groups. No cases of valve thrombosis were recorded. Conclusions: Selected patients with a degenerated TAV may be safely and successfully treated by means of a second TAVR. This finding is of crucial importance for the adoption of the TAVR technology in a lower risk and younger population. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04500964.

27 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CSChristopher Strong
Christopher Strong
AFAntónio Ferreira
António Ferreira
RTRui Teles
Rui Teles
GMGustavo Mendes
Gustavo Mendes
JAJoão Abecasis
João Abecasis
MMMiguel Mendes
Miguel Mendes
Coronary CT angiography (CTA) is currently considered a reliable method to exclude obstructive coronary artery disease (CAD) before valvular heart surgery in patients with low pretest probability. However, its role in excluding obstructive CAD before transcatheter aortic valve implantation (TAVI) is less well established. Single-center retrospective study where patients with severe symptomatic aortic stenosis underwent both CTA and invasive coronary angiography (ICA) as part of TAVI planning. CTA exams were conducted on a 64-slice dual source scanner, with a median interval of 45 days to ICA (IQR 25–75 [13–82]). In both tests, obstructive CAD was defined as a ≥50% stenosis in an epicardial vessel ≥2 mm diameter. Per-patient, per-vessel and per-proximal segment analyses were conducted, excluding and including non-evaluable segments. The study included 200 patients (120 women, mean age 83 ± 6 years). The prevalence of obstructive CAD on ICA was 35.5% (n = 71). On a per-patient analysis (assuming non-evaluable segments as stenotic), CTA showed sensitivity of 100% (95% CI, 95–100%), specificity of 42% (95% CI, 33–51%), and positive and negative predictive values of 48% (95% CI, 44–51%) and 100% (95% CI, 92–100%), respectively. CTA was able to exclude obstructive CAD in 54 patients (27%), in whom ICA could have been safely withheld. Despite the high rate of inconclusive tests, pre-procedural CTA is able to safely exclude obstructive CAD in a significant proportion of patients undergoing TAVI, possibly avoiding the need for ICA in roughly one quarter of the cases.

14 August 2021 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
MGMario García Gómez
Mario García Gómez
JDJose Raúl Delgado‐Arana
Jose Raúl Delgado‐Arana
JHJonathan Halim
Jonathan Halim
FMFederico De Marco
Federico De Marco
CTCarlo Trani
Carlo Trani
Ignacio J. Amat-SantosIgnacio J. Amat-Santos
Ignacio J. Amat-Santos

6 July 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
CFChiara Fraccaro
Chiara Fraccaro
RTRui Teles
Rui Teles
DTDidier Tchétché
Didier Tchétché
FSFrancesco Saia
Francesco Saia
Francesco BedogniFrancesco Bedogni
Francesco Bedogni
GTGiuseppe Tarantini
Giuseppe Tarantini